GSK Told to Update Avandia Warnings (Pharmaceutical Executive)

Last week, FDA ruled that GlaxoSmithKline's diabetes treatment Avandia (rosiglitazone) would receive a black-box warning signaling to doctors and prescribers that the medication could increase the chance of heart attack and angina in patients.